- ICH GCP
- Registro delle prove cliniche dell'UE
Ultime prove
EudraCT Number: 2004-005078-22 | Sponsor Protocol Number: QUETIAPINKOGNSCHIZOPHR | Start Date: 2005-04-18 | ||||||
Sponsor Name: Medical School of Hannover | ||||||||
Full Title: Quetiapin: Zur Sicherheit, Verträglichkeit und zum Einfluss auf kognitive Funktionen bei Patienten/innen mit einer schizophrenen Psychose Quetiapine: safety and influence on cognitive functions i... | ||||||||
Medical condition: Patients with schizophrenia, who are not in an acute state of psychosis at enrolment (PANSS score | ||||||||
|
||||||||
Population Age: Adults | Gender: Male, Female | |||||||
Trial protocol: DE (Completed) | ||||||||
Trial results: View results |
EudraCT Number: 2005-001380-61 | Sponsor Protocol Number: CSTI5710102E2 | Start Date: 2005-04-15 | |||||||||||
Sponsor Name: NOVARTIS FARMA | |||||||||||||
Full Title: An extension to a phase II open label study to determine the safety and anti-leukemic effects of STI571 in patients with Philadelphia chromosome positive chronic myeloid leukemia in myeloid blast c... | |||||||||||||
Medical condition: Ph+ CML in myeloid blast crisis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001382-33 | Sponsor Protocol Number: CSTI5710110E2 | Start Date: 2005-04-15 | |||||||||||
Sponsor Name: NOVARTIS FARMA | |||||||||||||
Full Title: An extension to a phase II study to determine the efficacy and the safety of STI571 in patients with chronic myeloid leukemia who are refractory to or intolerant of interferon-alpha | |||||||||||||
Medical condition: treatment of patients with CML who are refractory to or intolerant of interferon alpha. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-004158-23 | Sponsor Protocol Number: 3303 | Start Date: 2005-04-15 | |||||||||||
Sponsor Name: IST. DI RICERCHE FARMACOLOG. M. NEGRI | |||||||||||||
Full Title: DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL ON THE USE OF ACETYL-L-CARNITINE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) | |||||||||||||
Medical condition: Amyotrophic lateral sclerosis therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-004528-11 | Sponsor Protocol Number: BM18102 | Start Date: 2005-04-15 | |||||||||||
Sponsor Name: F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: Multicenter, double-blind, randomized, placebo-controlled, dose ranging phase 2 study to investigate efficacy, safety, tolerability and pharmacokinetics of the DPPIV inhibitor RO0730699 in patients... | |||||||||||||
Medical condition: Type 2 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) EE (Completed) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-005123-18 | Sponsor Protocol Number: 104020 | Start Date: 2005-04-15 | ||||||
Sponsor Name: GlaxoSmithKline | ||||||||
Full Title: A phase III, partially blind, randomised, primary vaccination study to assess the immunogenicity and safety of three different lots of GlaxoSmithKline (GSK) Biologicals’ live attenuated measles-mum... | ||||||||
Medical condition: Active immunization of healthy children during their second year of life against measles, mumps, rubella and varicella diseases. | ||||||||
|
||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||
Trial protocol: FI (Completed) DE (Completed) | ||||||||
Trial results: View results |
EudraCT Number: 2004-004876-36 | Sponsor Protocol Number: 05/Q0108/5 | Start Date: 2005-04-15 | ||||||
Sponsor Name: Addenbrookes Hospital NHS Trust | ||||||||
Full Title: AN INVESTIGATION INTO THE ROLE OF MATRIX METALLOPROTEINASES (MMP’s) IN LOWER LIMB VASCULAR RESTENOSIS | ||||||||
Medical condition: Post angioplasty and post vein graft stenosis. | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: GB (Completed) | ||||||||
Trial results: View results |
EudraCT Number: 2005-000427-42 | Sponsor Protocol Number: LT 2005 XX | Start Date: 2005-04-15 | ||||||
Sponsor Name: UK Children’s Cancer Study Group | ||||||||
Full Title: SIOPEL 5 (HCC-1) trial on the hepatocellular carcinoma family of tumours in children/adolescents and young adults | ||||||||
Medical condition: Hepatocellular carcinoma | ||||||||
|
||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||
Trial protocol: GB (Completed) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2004-002782-20 | Sponsor Protocol Number: H3E-MC-JMHH | Start Date: 2005-04-15 | ||||||
Sponsor Name: Eli Lilly and Company Limited | ||||||||
Full Title: A Phase 1 and 2 Clinical Trial of ALIMTA (Pemetrexed) in Combination with Carboplatin in Patients with Recurrent Ovarian or Primary Peritoneal Cancer | ||||||||
Medical condition: platinum sensitive recurrent ovarian or primary peritoneal cancer | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||
Trial protocol: DE (Completed) SE (Completed) | ||||||||
Trial results: View results |
EudraCT Number: 2004-004824-11 | Sponsor Protocol Number: ELBE-2005 | Start Date: 2005-04-15 | ||||||
Sponsor Name: Universitätshautklinik Kiel | ||||||||
Full Title: Role for pimecrolimus in restoring skin barrier function and normalizing epidermal lipid content and differentiation in atopic epidermis: a randomized, intra-patient, double-blind (right/left arm) ... | ||||||||
Medical condition: Atopic Dermatitis | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: DE (Completed) | ||||||||
Trial results: (No results available) |